# A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

> **NCT05711667** · PHASE3 · RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 105 (estimated)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Letermovir

## Key facts

- **NCT ID:** NCT05711667
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-11
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05711667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05711667, "A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05711667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*